home / stock / oryzf / oryzf news

ORYZF News and Press, Oryzon Genomics S.A. From 03/03/25

Stock Information
Company Name: Oryzon Genomics S.A.
Stock Symbol: ORYZF
Market: OTC
Menu
ORYZF ORYZF Quote ORYZF Short ORYZF News ORYZF Articles ORYZF Message Board
Get ORYZF Alerts

News, Short Squeeze, Breakout and More Instantly...
ORYZF - Oryzon Defines Phase III Trial Endpoints for Agitation and Aggression in BPD with Input From New Clinical Advisory Board

Leading US psychiatric experts join Oryzon’s Clinical Advisory Board (CAB) to advance Phase III development of vafidemstat in Borderline Personality Disorder (BPD) CAB and Oryzon establish primary and key secondary endpoints for Phase III trial, aligned with FDA standards O...
ORYZF - ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting

All resolutions were approved MADRID, Spain and CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A., a clinical-stage biopharmaceutical company focused on epigenetics for the development of therapies for diseases with significant unmet medical needs, today announced t...

ORYZF - ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2024

Reshaping its Board of Directors at the upcoming Shareholders’ meeting with the aim of enhancing U.S. outreach Preparations for PORTICO-2 Phase III trial with vafidemstat in agitation/aggression in Borderline Personality Disorder ongoing Final data from REIMAGINE proof-of-c...

ORYZF - ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences

The Phase IIa study REIMAGINE evaluated the safety and preliminary efficacy of vafidemstat in agitation/aggression in borderline personality disorder (BPD), attention-deficit/hyperactivity disorder (ADHD) and autistic spectrum disorder (ASD) Vafidemstat demonstrated a relevant clinical be...
ORYZF - ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders' Meeting

Aimed at enhancing U.S. outreach, investor relations, corporate dialogue, and business development (BD) capabilities MADRID and CAMBRIDGE, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging...

ORYZF - ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome

Exploring the combination with azacitidine Study led by Medical College of Wisconsin MADRID and CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop th...

ORYZF - ORYZON announces appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor

MADRID, Spain and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, is pleased to announce the appointment of ...
ORYZF - ORYZON Announces First Patient Dosed in NCI-Sponsored Iadademstat in Combination With Venetoclax and Azacitidine Clinical Trial in First Line Acute Myeloid Leukemia

Study conducted under the CRADA agreement between NCI and Oryzon MADRID, Spain and CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases...

ORYZF - ORYZON to Provide Corporate Progress Updates at Several Events in January-February

8th Sachs Annual Neuroscience Innovation Forum 14th Annual LifeSci Advisors Corporate Access Event Invest Securities BioMed Forum 2025 MidCap Events Frankfurt 2025 Bio-Neuroscience 2025 MADRID and CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Oryzon G...

Previous 10 Next 10